Arcus biosciences to present new data from casdatifan, a hif-2a inhibitor, in an oral presentation at the 2025 asco gu symposium

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that data from the arc-20 study will be presented in a rapid oral session at the 2025 american society of clinical oncology (asco) genitourinary (gu) cancers symposium taking place february 13 – 15, 2025, in san francisco, ca. the oral presentation will highligh.
RCUS Ratings Summary
RCUS Quant Ranking